Evidence map›Paper›PMID 39380156›Full record

ArticleInfluenza and other respiratory viruses2024

Meeting Report From "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned From the COVID-19 Pandemic".

Florian Krammer, Jacqueline M Katz, Othmar G Engelhardt, Diane J Post, Paul C Roberts, Sheena G Sullivan, S Mark Tompkins, Christopher Chiu, Stacey Schultz-Cherry, Rebecca Jane Cox

Abstract read
In one paragraph

Article in Influenza and other respiratory viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jacqueline M KatzThe Task Force for Global Health, Decatur, Georgia, USA.
Othmar G EngelhardtScience Research & Innovation, Medicines and Healthcare products Regulatory Agency, Potters Bar, UK.
Diane J PostDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (DMID/NIAID/NIH), Rockville, Maryland, USA.
Paul C RobertsDivision of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health (DMID/NIAID/NIH), Rockville, Maryland, USA.
Sheena G SullivanWHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, and Department of Infectious Diseases, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.ORCID 0000-0002-0856-0294
S Mark TompkinsCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.ORCID 0000-0002-1523-5588
Christopher ChiuDepartment of Infectious Diseases, Imperial College London, London, UK.
Stacey Schultz-CherryDepartment of Host-Microbe Interactions, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Rebecca Jane CoxInfluenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway.ORCID 0000-0002-8341-4078

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis report summarizes the discussions and conclusions from the "Correlates of Protection for Next Generation Influenza Vaccines: Lessons Learned from the COVID-19 Pandemic" meeting, which took place in Seattle, USA, from March 1, 2023, to March 3, 2023.

conclusionsDiscussions around influenza virus correlates of protection and their use continued from where the discussion had been left off in 2019. While there was not much progress in the influenza field itself, many lessons learned during the coronavirus disease 2019 (COVID-19) pandemic, especially the importance of mucosal immunity, were discussed and can directly be applied to influenza correlates of protection.

Indexed as

COVID-19Influenza, HumanInfluenza VaccinesHumansImmunity, MucosalPandemicsSARS-CoV-2Influenza Vaccinescorrelates of protection (CoP)COVID‐19influenzainfluenza vaccinemucosal immunitySARS‐CoV‐2

Identifiers

PMID39380156
PMCPMC11461279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.